CN116036234A - 一种用于治疗骨质疏松的药剂 - Google Patents
一种用于治疗骨质疏松的药剂 Download PDFInfo
- Publication number
- CN116036234A CN116036234A CN202310067287.9A CN202310067287A CN116036234A CN 116036234 A CN116036234 A CN 116036234A CN 202310067287 A CN202310067287 A CN 202310067287A CN 116036234 A CN116036234 A CN 116036234A
- Authority
- CN
- China
- Prior art keywords
- apce1
- medicament
- antibacterial peptide
- mesenchymal stem
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 33
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 32
- 230000035755 proliferation Effects 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 230000009818 osteogenic differentiation Effects 0.000 claims abstract description 10
- 210000001185 bone marrow Anatomy 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 15
- 230000002308 calcification Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 101000636792 Amolops loloensis Temporin Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004072 osteoblast differentiation Effects 0.000 description 4
- 230000002188 osteogenic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 230000000431 effect on proliferation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
分组 | OD值 |
对照组 | 0.510±0.020 |
GzLEAP-2A | 0.512±0.039 |
OdTo3 | 0.484±0.024 |
ApCe1 | <![CDATA[0.729±0.043<sup>**</sup>]]> |
OdMa1 | 0.500±0.036 |
LiVe1 | <![CDATA[0.439±0.031<sup>*</sup>]]> |
Amolopin P1 | <![CDATA[0.613±0.027<sup>**</sup>]]> |
Peoriaerin IBSD35 | 0.507±0.035 |
分组 | OD值 |
对照组 | 0.495±0.025 |
2.5μg/ml ApCe1 | <![CDATA[0.561±0.031<sup>*</sup>]]> |
5μg/ml ApCe1 | <![CDATA[0.609±0.041<sup>*</sup>]]> |
10μg/ml ApCe1 | <![CDATA[0.737±0.045<sup>**</sup>]]> |
20μg/ml ApCe1 | <![CDATA[0.881±0.053<sup>***</sup>]]> |
40μg/ml ApCe1 | <![CDATA[0.880±0.058<sup>***</sup>]]> |
80μg/ml ApCe1 | <![CDATA[0.886±0.046<sup>***</sup>]]> |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310067287.9A CN116036234B (zh) | 2023-01-17 | 2023-01-17 | 一种用于治疗骨质疏松的药剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310067287.9A CN116036234B (zh) | 2023-01-17 | 2023-01-17 | 一种用于治疗骨质疏松的药剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116036234A true CN116036234A (zh) | 2023-05-02 |
CN116036234B CN116036234B (zh) | 2024-02-06 |
Family
ID=86132937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310067287.9A Active CN116036234B (zh) | 2023-01-17 | 2023-01-17 | 一种用于治疗骨质疏松的药剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116036234B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118028212A (zh) * | 2024-04-12 | 2024-05-14 | 广东医科大学附属医院 | 土元外泌体在制备抗骨质疏松药物中的应用、药物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110166063A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
CN102348723A (zh) * | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
US20140221278A1 (en) * | 2005-06-17 | 2014-08-07 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
CN105816912A (zh) * | 2016-03-09 | 2016-08-03 | 上海交通大学医学院附属第九人民医院 | 一种抗感染和促进成骨分化的抗菌肽修饰钛合金假体及其制备方法 |
CN109134662A (zh) * | 2017-06-27 | 2019-01-04 | 中国农业科学院饲料研究所 | 一种可视化抗菌肽融合蛋白及其制备方法和其应用 |
CN109553661A (zh) * | 2018-11-22 | 2019-04-02 | 广州天宝颂原生物科技开发有限公司 | ApcE2蛋白突变体及其应用 |
CN112245567A (zh) * | 2019-07-22 | 2021-01-22 | 上海交通大学医学院附属第九人民医院 | 一种抗菌及促成骨复合支架材料 |
-
2023
- 2023-01-17 CN CN202310067287.9A patent/CN116036234B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140221278A1 (en) * | 2005-06-17 | 2014-08-07 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
US20110166063A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
CN102348723A (zh) * | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
CN105816912A (zh) * | 2016-03-09 | 2016-08-03 | 上海交通大学医学院附属第九人民医院 | 一种抗感染和促进成骨分化的抗菌肽修饰钛合金假体及其制备方法 |
CN109134662A (zh) * | 2017-06-27 | 2019-01-04 | 中国农业科学院饲料研究所 | 一种可视化抗菌肽融合蛋白及其制备方法和其应用 |
CN109553661A (zh) * | 2018-11-22 | 2019-04-02 | 广州天宝颂原生物科技开发有限公司 | ApcE2蛋白突变体及其应用 |
CN112245567A (zh) * | 2019-07-22 | 2021-01-22 | 上海交通大学医学院附属第九人民医院 | 一种抗菌及促成骨复合支架材料 |
Non-Patent Citations (3)
Title |
---|
AMELIA RICHTER等: ""Associating Biological Activity and Predicted Structure of Antimicrobial Peptides from Amphibians and Insects", ANTIBIOTICS, vol. 11, no. 12, pages 1 - 14 * |
曲成明;殷楚强;李利平;解维峰;: "介入栓塞术联合锁定钢板骨水泥填充治疗长骨转移癌病理性骨折", 中国矫形外科杂志, no. 18 * |
罗万荣等: "不同浓度人源性抗菌肽LL-37/PLGA/β-TCP复合支架对兔骨髓间充质干细胞增殖、分化的影响", 中国医学创新, vol. 17, no. 12, pages 6 - 11 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118028212A (zh) * | 2024-04-12 | 2024-05-14 | 广东医科大学附属医院 | 土元外泌体在制备抗骨质疏松药物中的应用、药物 |
Also Published As
Publication number | Publication date |
---|---|
CN116036234B (zh) | 2024-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116036234B (zh) | 一种用于治疗骨质疏松的药剂 | |
CN113527467B (zh) | 鲟鱼鱼皮胶原多肽提取方法、应用、化妆品原料及其制备方法 | |
Anderson et al. | Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents | |
CN114606186B (zh) | 一种提高脐带间充质干细胞增殖的方法 | |
CN108057116A (zh) | 干细胞组合物在皮肤损伤治疗药物中的应用 | |
Zhang et al. | External volume expansion adjusted adipose stem cell by shifting the ratio of fibronectin to laminin | |
CN113197919A (zh) | 鹿茸干细胞外泌体在制备改善或治疗骨关节炎和延缓细胞衰老的产品中的应用 | |
WO2020258828A1 (zh) | 组织工程骨支架及其制备方法 | |
CN110840882A (zh) | 一种治疗骨质疏松的组合物 | |
CN116426469B (zh) | LAP2α在间充质干细胞成脂向分化中的应用 | |
CN112138159A (zh) | 乳酸脱氢酶在组织炎症和纤维化治疗中的应用 | |
CN113577389A (zh) | 一种来自猪耳软骨的脱细胞软骨材料及制备方法和应用 | |
CN110917217B (zh) | 肌肉干细胞在制备抗炎药物中的应用 | |
CN114836377B (zh) | 一种干细胞体外成骨诱导分化方法 | |
Zanardo et al. | Decellularized splenic matrix as a scaffold for spleen bioengineering | |
WO2022007284A1 (zh) | 一种钙通道抑制剂氧海罂粟碱在骨关节炎中的应用 | |
CN117018295B (zh) | 一种成活率高的自体脂肪移植方法 | |
CN116617208B (zh) | 一种组合物在提高衰老牙周膜干细胞性能中的应用 | |
CN116440251B (zh) | 血吸虫来源多肽在制备预防和/或治疗缺血再灌注的药物中的应用 | |
CN115089716B (zh) | Bmp4作为作用靶点在制备治疗糖尿病心肌病药物中的应用 | |
KR20200001370A (ko) | 지방줄기세포배양용 배지 조성물 제조방법, 지방줄기세포배양용 배지 조성물 제조방법과 줄기세포 유효성분 3저 추출법을 이용한 줄기세포파쇄추출물(쉘드줄기세포) 제조방법, 이를 이용한 항관절염 치료용 조성물, 이를 이용한 염증억제 효과를 갖는 조성물 및 세포재생 효과를 갖는 조성물 | |
TWI841414B (zh) | 包含外泌體及生物巨分子之組合物、包含其的醫藥組成物及其用途 | |
CN112472869B (zh) | 一种用于治疗感染性大段骨缺损组织工程骨支架及其制备方法和应用 | |
CN118222496A (zh) | 髌下脂肪垫干细胞的培养基及培养方法 | |
Wang et al. | Research Article Evaluating the Bone Tissue Regeneration Capability of the Chinese Herbal Decoction Danggui Buxue Tang from a Molecular Biology Perspective |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230903 Address after: 266000 unit 202, building 15, Max business Hongwan, 17 Guangbo Road, high tech Zone, Qingdao, Shandong Province Applicant after: Qingdao Situo Xinyuan Cell Medicine Co.,Ltd. Address before: No. 127 Siliu South Road, Shibei District, Qingdao City, Shandong Province, 266300 Applicant before: QINGDAO CENTRAL Hospital |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240115 Address after: No. 127 Siliu South Road, Shibei District, Qingdao City, Shandong Province, 266300 Applicant after: QINGDAO CENTRAL Hospital Address before: 266000 unit 202, building 15, Max business Hongwan, 17 Guangbo Road, high tech Zone, Qingdao, Shandong Province Applicant before: Qingdao Situo Xinyuan Cell Medicine Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |